Key result
Anticoagulation choice between heparin and bivalirudin during percutaneous coronary intervention must balance the minimization of thrombotic events against the risk of bleeding.
Why the study?
Does bivalirudin compared to heparin improve outcomes in patients with STEMI and NSTEMI undergoing PCI?
Does bivalirudin compared to heparin improve outcomes in patients with STEMI and NSTEMI undergoing PCI?
Answers are grounded in this paper and cite their sources.
This editorial discusses the ongoing debate regarding the optimal choice of anticoagulation (heparin vs bivalirudin) during PCI for STEMI and NSTEMI.
Percutaneous coronary intervention (PCI) is the cornerstone of management for patients with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) (1-6). Anticoagulation is routinely administered during PCI in order to minimize the risk of thrombotic events. However, the choice of anticoagulation should be balanced with the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Elgendy et al. (2017) studied this question. Anticoagulation choice between heparin and bivalirudin during percutaneous coronary intervention must balance the minimization of thrombotic events against the risk of bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: